肺超声引导治疗策略在心血管高危的慢性血液透析患者中的随机多中心试验
这项国际多中心随机对照试验纳入367例心血管高危的慢性血液透析患者,评估肺超声引导的超滤和药物治疗策略是否改善复合终点(全因死亡、非致死性心肌梗死、失代偿性心衰)。结果显示干预组肺淤血缓解率显著更高(78% vs 56%),但主要复合终点无显著差异(HR 0.88;95%CI 0.63-1.24)。
要点
- 肺超声引导治疗可安全有效地缓解透析患者肺淤血。
- 主要复合终点(死亡、心梗、失代偿性心衰)未显著改善。
- 事后分析提示复发性失代偿性心衰和心血管事件风险降低。
核心结论
- 肺超声引导治疗策略有效缓解肺淤血,但未比常规治疗更改善主要或次要终点。
研究设计与样本
- 国际多中心随机对照试验(NCT02310061),纳入367例心血管高危的慢性血液透析患者,干预组183例,对照组180例。
主要发现
- 平均随访1.49年,干预组肺淤血缓解率78%,对照组56%,干预安全。
- 主要复合终点两组无显著差异(HR 0.88;95%CI 0.63-1.24)。
- 全因和心血管住院风险、左心室质量及功能变化两组无差异。
- 事后分析显示复发性失代偿性心衰(HR 0.37;95%CI 0.15-0.93)和心血管事件(HR 0.63;95%CI 0.41-0.97)风险降低。
- 患者报告结局(抑郁和SF36生活质量问卷)两组无差异。
临床怎么用
- 肺超声可用于指导透析中超滤和药物治疗以缓解肺淤血,但未证实可改善硬终点。
局限性
- 主要终点未达显著差异,部分获益仅为事后分析,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung congestion is a risk factor for all-cause and cardiovascular mortality in patients on chronic hemodialysis, and its estimation by ultrasound may be useful to guide ultrafiltration and drug therapy in this population. In an international, multi-center randomized controlled trial (NCT02310061) we investigated whether a lung ultrasound-guided treatment strategy improved a composite end point (all-cause death, non-fatal myocardial infarction, decompensated heart failure) vs usual care in patients receiving chronic hemodialysis with high cardiovascular risk. Patient-Reported Outcomes (Depression and the Standard Form 36 Quality of Life Questionnaire, SF36) were assessed as secondary outcomes. A total of 367 patients were enrolled: 183 in the active arm and 180 in the control arm. In the active arm, the pre-dialysis lung scan was used to titrate ultrafiltration during dialysis and drug treatment. Three hundred and seven patients completed the study: 152 in the active arm and 155 in the control arm. During a mean follow-up of 1.49 years, lung congestion was significantly more frequently relieved in the active (78%) than in the control (56%) arm and the intervention was safe. The primary composite end point did not significantly differ between the two study arms (Hazard Ratio 0.88; 95% Confidence Interval: 0.63-1.24). The risk for all-cause and cardiovascular hospitalization and the changes of left ventricular mass and function did not differ among the two groups. A post hoc analysis for recurrent episodes of decompensated heart failure (0.37; 0.15-0.93) and cardiovascular events (0.63; 0.41-0.97) showed a risk reduction for these outcomes in the active arm. There were no differences in patient-reported outcomes between groups. Thus, in patients on chronic hemodialysis with high cardiovascular risk, a treatment strategy guided by lung ultrasound effectively relieved lung congestion but was not more effective than usual care in improving the primary or secondary end points of the trial.
引用
- Zoccali C, Torino C, Mallamaci F, et al. A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk. Kidney Int. 2021. PMID: 34418415. doi:10.1016/j.kint.2021.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。